Merit Medical Systems

Merit Medical Systems is the mid-cap medical-device manufacturer that has produced the most paradoxical 2025-2026 setup in healthcare: revenue growing 7.5% year-over-year, earnings growing 38.8%, and yet the stock down 40% from its 52-week high of 100 USD to current 61.36 USD. The disconnect is genuine and creates the asymmetric opportunity — the operating business is performing better than the chart implies.

The company designs, manufactures and sells single-use medical products for interventional and diagnostic procedures across two segments. Cardiovascular (approximately 88% of revenue) includes peripheral intervention products (angiography, drainage, embolotherapy), oncology procedure tools (soft-tissue biopsy products) and access devices (micropuncture kits, sheaths, guide wires). Endoscopy (12% of revenue) sells single-use endoscopy instruments and consumables. The product portfolio runs over 7,000 SKUs across more than 100 countries — a textbook diversified medical-device platform with low single-product concentration risk.

The 2024 stock-peak-and-collapse narrative was driven by three temporary factors: (1) the BD-Bard acquisition spree fear that Merit would be acquired at a premium, then disappointment when no deal materialized; (2) China volume-based-procurement pricing pressure on certain specialty products (approximately 4% revenue exposure); (3) hospital-capex deferral spike in Q4/2024 that has since reversed. The 2025-2026 reality is that revenue is reaccelerating, the operating margin is expanding (11.5% trailing versus 9.2% a year ago), and free cash flow conversion is improving toward the 15-18% target.

The forward P/E of 13.9x against analyst mean target of 90.64 USD (48% upside) suggests sell-side conviction has not faded — the consensus expects normalized earnings power to assert itself by mid-2026. The buy rating with no sell ratings reinforces this view.

Institutional ownership has been a quiet accumulation story since the stock peaked in mid-2024. Q1/2026 13F: Wellington Management at 8.2% (added through the 60-70 USD range across Q4/2025 and Q1/2026), T. Rowe Price at 5.4%, Capital Group at 4.9% (initiated in Q3/2025). The passive base (Vanguard 11%, BlackRock 10%, State Street 5%) is the standard Russell 2000 medical-device composition.

The most notable signal is the absence of selling: founder and chairman Fred Lampropoulos owns approximately 4.5% of the stock and has not sold a single share through the entire drawdown. Two independent directors purchased a combined 480 thousand USD between September 2025 and February 2026 at prices ranging from 62-74 USD. CFO Raul Parra exercised options in March 2026 but retained 100% of vested shares — a rare full-retention move that signals personal conviction.

Short interest at 7.35% is moderate for a name down 40% from highs — bears are not aggressively pushing for further downside. Days-to-cover at 4.1 suggests balanced positioning. There is no organized activist position despite the obvious sum-of-the-parts case (Cardiovascular segment alone would fetch a premium standalone valuation). The Lampropoulos family-controlled-governance structure makes activist intervention unlikely.

Merit Medical's valuation tells a clear story: trailing P/E 26.5x reflects one-time charges; forward P/E 13.9x is the more meaningful metric. EV/EBITDA at 12.7x is below the medical-device peer median of 14-16x. Price-to-sales at 2.37x is below 5-year average of 2.85x. Every multiple frame points to current valuation being modestly depressed relative to history and notably depressed relative to peers.

The sum-of-the-parts adds a layer. Cardiovascular segment (interventional radiology, peripheral intervention, oncology biopsy) at 14x EBITDA (specialty-medical-device peer set) = approximately 3.4 billion USD; Endoscopy segment at 10x EBITDA (general medical-device peer set) = approximately 420 million USD; net debt of approximately 800 million USD; fair value of equity approximately 3.0-3.4 billion USD versus current 3.66 billion USD cap. The sum-of-the-parts is roughly fair value at current levels, meaning the upside lever is multiple expansion rather than fundamental misvaluation.

Free cash flow yield of 4.9% provides downside support. The forward consensus FCF for 2027 is 240 million USD, implying 6.6% forward FCF yield at current price — attractive enough to attract value-oriented healthcare investors. Dividend yield 0% (the company has not paid a dividend historically but management has signaled openness to small initiation in 2026-2027).

1. August 2026: Q2 2026 earnings — second consecutive quarter likely to confirm sustained margin-expansion trajectory
2. Q4 2026: FY2027 guidance — first formal commitment to 13-14% operating margin path
3. 2027: Potential dividend initiation — would broaden the institutional holder base

Merit Medical is the textbook case of a quality compounder that the market has temporarily overlooked because of the 2024 peak-and-collapse narrative. The operational data (revenue growth, margin expansion, FCF conversion) tells the opposite story of what the chart suggests. The Lampropoulos family-controlled governance means you are aligned with patient capital, not quarterly performance pressure.

My personal approach for setups like this is sizing of 2-3% of equity with a hard stop at 53 USD (below the recent 52-week low and the 2024-pre-collapse trading range). The first add-on signal is the Q2/2026 earnings confirming sustained margin expansion — that removes the largest analytical objection. Without that, the boring base case still pays out as the forward multiple normalizes toward peers over 12-18 months. Target 80-85 USD as the central case (sub-consensus), 105-115 USD on full multiple recovery to peer median. Not a fast trade — but the asymmetry favors the long side at current valuation.